Skip to main content
TipRanks
Go Ultimate75% OFF

Immucell (ICCC) Stock Price & Analysis

81 Followers

ICCC Stock Chart & Stats

$11.17-$0.08(-0.71%)
At close: 4:00 PM EST
$9.5$10$10.5$11Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$11.10 - $11.50
52-Week Range
$4.52 - $12.10
Previous Close
$11.25
Volume
N/A
Average Volume (3M)
12.96K
Market Cap
$101.55M
Enterprise Value
$95.21M
Total Cash (Recent Filing)
$7.91M
Total Debt (Recent Filing)
$12.01M
Price to Earnings (P/E)
55.9
Beta
0.10
Next Earnings
Feb 23, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Revenue And Customer Growth

Broad-based sales and distributor-volume growth indicates stronger product adoption and commercial execution, not merely isolated customer activity. Continued expansion can improve operating leverage, strengthen channel relationships, and provide a durable base for scaling the company’s cattle-health portfolio.

Improved Balance-Sheet Resilience

Meaningfully lower debt and a larger equity cushion improve financial flexibility as the company funds capacity expansion. Reduced leverage should lower balance-sheet pressure and give management more room to absorb operating volatility while investing in commercial growth.

Capacity Expansion Supports Growth

Removing the current drying bottleneck could allow ImmuCell to convert customer demand into higher shipments and revenue over the next several quarters. The planned capacity increase also supports operational scale and reduces dependence on constrained existing production capacity.

Bears Say

Thin And Volatile Profitability

Although the company has returned to profit, modest margins leave limited protection against cost increases or execution setbacks. The history of losses and volatile earnings makes it harder to establish that the recent improvement is durable rather than an early-stage recovery.

Historical Supply And Contamination Issues

Prior contamination-related disruptions demonstrate that production problems can materially affect product availability, customer service, and revenue realization. Even with recovery underway, the episode raises execution risk around maintaining consistent supply as demand and output expand.

Re-Tain Program Failure

Halting Re-Tain removes a development opportunity and leaves the company more reliant on its existing cattle-health products for future growth. The failed trials and manufacturing approval setback also represent sunk development effort without a clear commercial return.

Immucell News

ICCC FAQ

What was Immucell’s price range in the past 12 months?
Immucell lowest stock price was $4.52 and its highest was $12.10 in the past 12 months.
What is Immucell’s market cap?
Immucell’s market cap is $101.55M.
When is Immucell’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Immucell’s earnings last quarter?
Immucell released its earnings results on Nov 12, 2026. The company reported $0.102 earnings per share for the quarter.
Is Immucell overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Immucell pay dividends?
Immucell does not currently pay dividends.
What is Immucell’s EPS estimate?
Immucell’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immucell have?
Immucell has 9,091,361 shares outstanding.
What happened to Immucell’s price movement after its last earnings report?
Immucell reported an EPS of $0.102 in its last earnings report. Following the earnings report the stock price went up 5.186%.
Which hedge fund is a major shareholder of Immucell?
Hedge funds hold Immucell shares: the largest hedge-fund position in Immucell is 72,327,822 shares, and hedge funds decreased their holdings by 973.0 shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology